证券代码：002626 证券简称：金达威 公告编号：2025-071 厦门金达威集团股份有限公司 向不特定对象发行可转换公司债券发行结果公告 一、本次可转债原股东优先配售结果 本次发行原股东优先配售的缴款工作已于2025年8月20日（T日）结束，本 次发行向原股东优先配售金威转债总计为10,790,785张，即1,079,078,500元，占 本次发行总量的83.49%。 二、本次可转债网上认购结果 1 本次发行原股东优先配售后余额部分（含原股东放弃优先配售部分）的网 上认购缴款工作已于 2025 年 8 月 22 日（T+2 日）结束。本公告一经刊出即视 同向已参与网上申购并中签且及时足额缴款的网上投资者送达获配通知。 根据深交所和中国结算深圳分公司提供的数据，本次发行的保荐人（主承 销商）做出如下统计： 保荐人（主承销商）：广发证券股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 厦门金达威集团股份有限公司（以下简称"发行人"或"公司"）向不特定对 象发行可转换公司债券（以下简称"可转债"）已获得中国证券监督管理委员会 证监许可〔2024〕15 ...

Core Viewpoint - Xiamen Jindawei Group Co., Ltd. is issuing convertible bonds to unspecified investors, with a focus on ensuring compliance with relevant regulations and providing accurate information disclosure [1][2]. Group 1: Issuance Details - The convertible bonds will be offered to existing shareholders first, with any remaining bonds available to the public through the Shenzhen Stock Exchange [2]. - The issuance process includes important reminders regarding subscription, payment, and handling of abandoned subscriptions by investors [2][3]. - If the total subscriptions do not reach 70% of the issuance amount, the issuer and underwriter may consider suspending the issuance [3]. Group 2: Subscription and Allocation - The underwriter will assume responsibility for any shortfall in subscriptions, with a base amount of 1,292.3948 million yuan [3]. - The maximum underwriting amount is capped at 30% of the total issuance, which is approximately 387.7184 million yuan [3]. - Investors who abandon their subscriptions will be restricted from participating in new stock offerings for six months [4][5]. Group 3: Lottery Results - A lottery for the allocation of the convertible bonds was conducted, with a total of 213,316 winning numbers announced [5]. - Each winning number allows for the subscription of 10 bonds, equivalent to 1,000 yuan [5].

Core Viewpoint - Xiamen Jindawei Group Co., Ltd. is issuing convertible bonds to unspecified investors, with a total issuance amount of 1,292.3948 million yuan, priced at 100 yuan per bond, totaling 12,923,948 bonds [5][6]. Group 1: Issuance Details - The issuance is organized in accordance with relevant regulations, including the Securities Law of the People's Republic of China and the Shenzhen Stock Exchange's guidelines [1]. - The original shareholders have priority in subscribing to the bonds, with any remaining amount available for public investors through the Shenzhen Stock Exchange [2][3]. - The issuance process includes important reminders regarding subscription, payment, and handling of abandoned subscriptions by investors [2][3]. Group 2: Subscription Results - The total number of bonds subscribed by original shareholders was 10,790,785, achieving a 100% allocation rate [5]. - Public investors submitted a total of 87,109,888,590 valid applications, with a final allocation of 2,133,160 bonds, resulting in a low winning rate of approximately 0.0024% [5]. - The total number of applications received was 87,120,679,375, with the remaining 3 bonds being underwritten by the lead underwriter [5]. Group 3: Future Actions - The lead underwriter will conduct a lottery draw for the allocation results, which will be announced on August 22, 2025 [5]. - The listing date for the convertible bonds will be announced separately [5].

Group 1 - The core viewpoint of the articles highlights a significant increase in the number of investors participating in convertible bond subscriptions, reflecting a recovery in the A-share market and heightened investor confidence in equity markets [1][2][3] Group 2 - The number of new investors in convertible bond subscriptions has surged by 820,000 in just two months, bringing the total to over 8.7 million participants [1][2] - The recent performance of convertible bonds has been strong, with new bonds like the Ber25 and Guangke bonds seeing substantial price increases of over 50% and 40% respectively since their listings [4][6] - The overall A-share market has seen a significant increase in new account openings, with 1.456 million new accounts opened in the first seven months of 2025, a year-on-year increase of 36.88% [3] - The financing balance in the A-share market has also risen, reaching 21,329.69 billion yuan, an increase of over 340 billion yuan since May [3] - The high performance of newly listed convertible bonds is attributed to their long remaining terms and the influx of new funds, which have driven up their valuations [9][10]

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - On August 18, 2025, Jindawei announced plans to issue convertible bonds worth up to 1.292 billion yuan on August 20, 2025, through online distribution. The funds will be used for projects such as the Coenzyme Q10 Reconstruction and Expansion Project, the Annual Production of 30,000 Tons of Allulose and 5,000 Tons of Inositol Construction Project, the Information System Construction Project, and to supplement working capital [1][12]. - The initial conversion price of Jinwei Convertible Bond is 19.59 yuan. As of August 19, 2025, the bond's parity is 99.95 yuan, and the estimated conversion premium rate on the first - day of listing is in the range of 33% - 36%, with a target price of 133 - 136 yuan. It is recommended to actively subscribe [2][19]. - The estimated first - day new bond subscription winning rate is around 0.0061% - 0.0072% [20]. 3. Summary According to the Directory 3.1. Jinwei Convertible Bond New Bond Analysis and Investment Recommendations 3.1.1. Analysis of Convertible Bond Basic Terms - The issuance methods of Jinwei Convertible Bond are priority placement and online distribution, with a debt and issuer rating of AA. The issuance scale is 1.292 billion yuan, the initial conversion price is 19.59 yuan, the bond parity is 99.95 yuan, and the pure bond value is 98.2 yuan. The game terms are normal, with high issuance scale, good liquidity, acceptable rating, and good bond floor protection. It is easy for institutions to include it in their portfolios, and there is no objection to primary participation [2][14]. 3.1.2. Analysis of New Bond Initial Listing Price - The company mainly engages in the R & D, production, and sales of nutritional health foods (including raw materials and end - products) and feed additives. The funds raised from this issuance will be used for specific projects, which are in line with industry trends, can enhance the company's market competitiveness, optimize its capital structure, and support its development [18]. - The target price of the convertible bond on the first day of listing is 133 - 136 yuan, and it is recommended to actively subscribe. Considering the market environment and parity level, the estimated conversion premium rate on the first - day of listing is in the range of 33% - 36% [2][19]. 3.1.3. Analysis of Convertible Bond New Bond Subscription Winning Rate - As of the end of 2024, the top two shareholders held 53.39% of the shares, and the top ten shareholders held 60.76%. Assuming the old shareholders' placement ratio is 53% - 61%, the scale available for the market is 507 million - 602 million yuan. Referring to recent bond issuances, the estimated winning rate is around 0.0061% - 0.0072% [20]. 3.2. Analysis of the Underlying Stock's Fundamental Situation 3.2.1. Company's Main Business and Industry Upstream and Downstream - The company is mainly involved in the R & D, production, and sales of nutritional health foods and feed additives. The upstream of the nutritional health food industry includes raw material producers, and the downstream includes brand operators and channel merchants. The upstream of the feed additive industry consists of raw material - providing industries, and the downstream is the feed manufacturing industry. Various factors such as raw material price fluctuations, industry development, and market competition affect the industry [21][22]. 3.2.2. Company's Operating Conditions - From 2022 to Q1 2025, the company's operating income showed an increasing trend, with year - on - year growth rates of - 16.78%, 3.1%, 4.43%, and 11.31% respectively. The company's comprehensive gross profit margin fluctuated slightly, and the net profit margin increased. The company's accounts receivable showed an upward trend, and the turnover rate fluctuated. The net profit attributable to the parent company began to grow [25][35][38]. 3.2.3. Company's Equity Structure and Major Subsidiaries - As of the end of 2024, the company's equity structure was relatively concentrated. The top two shareholders held 53.39% of the shares, and the top ten shareholders held 60.76%. The Wang family indirectly controlled 60.18% of the shares and was the actual controller. The company had 28 holding companies and 8 participating companies [42]. 3.2.4. Company's Business Characteristics and Advantages - The company has advantages in technological innovation, overseas operations, large - scale production, personnel reserves, and patents. It has multiple R & D platforms, overseas subsidiaries, rich production experience, a professional talent team, and 194 patents as of December 31, 2024 [44][47][48]. 3.2.5. Arrangement of This Fund - Raising Investment - The company plans to raise up to 1.292 billion yuan. The Coenzyme Q10 Reconstruction and Expansion Project, with a total investment of 320 million yuan and a planned use of 297 million yuan of the raised funds, aims to increase production capacity. The Annual Production of 30,000 Tons of Allulose and 5,000 Tons of Inositol Construction Project, with a total investment of 537 million yuan and a planned use of 464 million yuan of the raised funds, will supplement product categories. The Information System Construction Project, with a total investment of 153 million yuan and a planned use of 144 million yuan of the raised funds, will improve the company's informatization level [49][50][51].

证券之星消息，8月21日食品加工板块较上一交易日上涨0.13%，康比特领涨。当日上证指数报收于 3771.1，上涨0.13%。深证成指报收于11919.76，下跌0.06%。食品加工板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 833429 | 康比特 | 23.33 | 9.38% | 10.69万 | | 2.41亿 | | 605338 | 巴比食品 | 22.20 | 3.11% | 6.75万 | | 1.49亿 | | 002626 | 金达威 | 19.30 | 1.63% | 11.08万 | | 2.13亿 | | 605567 | 春雪食品 | 11.14 | 1.36% | 4.99万 | | 5557.76万 | | 603237 | 五芳斋 | 18.04 | 0.45% | 3.36万 | | 6040.88万 | | 002726 | 龙大美食 | 5.50 | 0.36% | 25.26万 | | 1.39亿 | | 000 ...

公 并 TIF (2025) 深罗证字第 10197 号 厦门金达威集团股份有限公司 -社会信用代码:91350200612033399C ff 江斌 衣人: 摇号现场公证 让事项: 、厦门金达威集团股份有限公司因网上发行可转换公 - 2025年 年 8 月 20 日向我处申请对投资者申购可转换 甲 请 司 债 务 签摇号进行现场公证,本处派出公证员伍斌、公证 公司侦 2025年8月21 日在深圳市罗湖区深南东路 5045 号 店 贝 物 室对厦门金达威集团股份有限公司发行可转换公 深 4 中 311 进行现场公证。 指 金达威集团股份有限公司经中国证监会核准向 l章 上发行可转换公司债券 2133160 张, 按每 10 者 মিশ্ৰী 场投 将有 213316 个号中签，发行办法及申购时间已在媒 者的日，投资者的配号总数 为 8710988859 th . 签率为 0.0024488149%。本次采用随机与均衡相结 行抽签,经检验,摇号机性能正常, 号码球数量齐 if 符合摇号条件。经现场摇号,摇出了中签号码 ( = y N. MT ITT 现场审查监督, 线 号真实、 合法、有效。 中华人民共和国广东 ...

证券代码：002626 证券简称：金达威 公告编号：2025-070 厦门金达威集团股份有限公司 向不特定对象发行可转换公司债券 中签号码公告 保荐人（主承销商）：广发证券股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 厦门金达威集团股份有限公司（以下简称"金达威"、"发行人"或"公司"） 和广发证券股份有限公司（以下简称"广发证券"或"保荐人（主承销商）"） 根据《中华人民共和国证券法》《上市公司证券发行注册管理办法》（证监会令[第 227 号]）、《证券发行与承销管理办法》（证监会令[第 228 号]）、《深圳证券交易 所上市公司证券发行与承销业务实施细则（2025 年修订）》（深证上[2025]268 号）、 《深圳证券交易所上市公司自律监管指引第 15 号——可转换公司债券（2025 年 修订）》（深证上[2025]223 号）、《深圳证券交易所上市公司自律监管指南第 1 号 ——业务办理（2025 年修订）》（深证上[2025]396 号）等相关规定组织实施本次 向不特定对象发行可转换公司债券（以下简称"可转债"或"金威转债" ...

证券代码：002626 证券简称：金达威 公告编号：2025-069 厦门金达威集团股份有限公司 向不特定对象发行可转换公司债券 网上发行中签率及优先配售结果公告 保荐人（主承销商）：广发证券股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示 厦门金达威集团股份有限公司（以下简称"金达威"、"发行人"或"公司"） 和广发证券股份有限公司（以下简称"广发证券"或"保荐人（主承销商）"） 根据《中华人民共和国证券法》《上市公司证券发行注册管理办法》（证监会令[第 227 号]）、《证券发行与承销管理办法》（证监会令[第 228 号]）、《深圳证券交易 所上市公司证券发行与承销业务实施细则（2025 年修订）》（深证上[2025]268 号）、 《深圳证券交易所上市公司自律监管指引第 15 号——可转换公司债券（2025 年 修订）》（深证上[2025]223 号）、《深圳证券交易所上市公司自律监管指南第 1 号 ——业务办理（2025 年修订）》（深证上[2025]396 号）等相关规定组织实施本次 向不特定对象发行可转换公司债券（以下简称"可 ...

1. Report Industry Investment Rating No relevant content provided. 2. Core Viewpoints of the Report - The expected listing price of Jinwei Convertible Bonds on the first day is between RMB 122.16 and RMB 135.89, and the expected winning rate is 0.0048%. Considering the good bond - bottom protection, average attractiveness in rating and scale, the expected conversion premium rate on the first - day of listing is around 29%. It is recommended to actively subscribe [1][13][14]. - Jindawei is a leading enterprise in the full - industry chain of nutritional health, with fluctuating revenue and net profit attributable to the parent company since 2020. The company's revenue mainly comes from the sales of health products, Coenzyme Q10, and Vitamin A series, and the product structure changes annually. The sales net profit margin and gross profit margin have decreased, while the sales expense ratio has increased [1][20][22]. 3. Summary According to the Directory 3.1. Convertible Bond Basic Information - Jinwei Convertible Bonds (127111.SZ) started online subscription on August 20, 2025, with a total issuance scale of RMB 1.292 billion. After deducting issuance fees, the net raised funds will be used for Coenzyme Q10 reconstruction and expansion projects, construction projects of 30,000 tons of allulose and 5,000 tons of inositol per year, information system construction projects, and supplementary working capital [1]. - The current bond - bottom valuation is RMB 98.24, and the YTM is 2.16%. The conversion parity is RMB 99.95, and the parity premium rate is 0.05%. The convertible bond terms are average, and the total share capital dilution rate is 9.76%, with relatively small dilution pressure on the equity [1][11][12]. 3.2. Investment Subscription Suggestions - The expected listing price of Jinwei Convertible Bonds on the first day is between RMB 122.16 and RMB 135.89. By referring to comparable targets and empirical results, the expected conversion premium rate on the first - day of listing is around 29% [13][14]. - The expected priority subscription ratio of original shareholders is 68.21%, and the expected winning rate is 0.0048% [17]. 3.3. Analysis of the Underlying Stock's Fundamental 3.3.1. Financial Data Analysis - Jindawei is a leading enterprise in the full - industry chain of nutritional health, mainly engaged in the R & D, production, and sales of health food and feed additives. Its revenue has fluctuated since 2020, with a compound growth rate of - 1.94% from 2020 - 2024. In 2024, the revenue was RMB 3.24 billion, a year - on - year increase of 4.43%. The net profit attributable to the parent company also fluctuated, with a compound growth rate of - 22.73% from 2020 - 2024. In 2024, it was RMB 342 million, a year - on - year increase of 23.59% [18][19][20]. - The company's revenue mainly comes from the sales of health products, Coenzyme Q10, and Vitamin A series. The proportion of health product sales revenue in the main business revenue has been increasing steadily since 2022, while the proportions of Coenzyme Q10 and Vitamin A series have been decreasing steadily [22]. - The company's sales net profit margin and gross profit margin have decreased, the sales expense ratio has increased, the financial expense ratio has decreased, and the management expense ratio has increased. The sales revenue is mainly from overseas markets [23]. 3.3.2. Company Highlights - The company uses synthetic biology as the underlying technology, applies it to the large - scale production of most raw material products, and actively uses synthetic biotechnology to layout new products [31]. - The company adheres to the principle of "strengthening innovation and leading the future", establishes a technology R & D and innovation system integrating enterprises, the market, and industry - university - research cooperation. It has multiple R & D platforms, more than 200 R & D personnel, and 194 domestic and foreign patent technologies as of December 31, 2024 [32].